These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 28738426)

  • 21. Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52-week, open-label, single-arm study.
    Seino Y; Yabe D; Sasaki T; Fukatsu A; Imazeki H; Ochiai H; Sakai S
    J Diabetes Investig; 2018 Mar; 9(2):332-340. PubMed ID: 28502112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liraglutide and Renal Outcomes in Type 2 Diabetes.
    Mann JFE; Ørsted DD; Brown-Frandsen K; Marso SP; Poulter NR; Rasmussen S; Tornøe K; Zinman B; Buse JB;
    N Engl J Med; 2017 Aug; 377(9):839-848. PubMed ID: 28854085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Change in albuminuria and eGFR following insulin sensitization therapy versus insulin provision therapy in the BARI 2D study.
    August P; Hardison RM; Hage FG; Marroquin OC; McGill JB; Rosenberg Y; Steffes M; Wall BM; Molitch M;
    Clin J Am Soc Nephrol; 2014 Jan; 9(1):64-71. PubMed ID: 24178969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial.
    von Scholten BJ; Persson F; Rosenlund S; Eugen-Olsen J; Pielak T; Faber J; Hansen TW; Rossing P
    Diabetes Obes Metab; 2017 Jun; 19(6):901-905. PubMed ID: 28105731
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment.
    Zobel EH; von Scholten BJ; Goldman B; Persson F; Hansen TW; Rossing P
    Diabetes Obes Metab; 2019 May; 21(5):1261-1265. PubMed ID: 30663196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial.
    Davies MJ; Bain SC; Atkin SL; Rossing P; Scott D; Shamkhalova MS; Bosch-Traberg H; Syrén A; Umpierrez GE
    Diabetes Care; 2016 Feb; 39(2):222-30. PubMed ID: 26681713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.
    Lapolla A; Frison V; Bettio M; Dal Pos M; Rocchini P; Panebianco G; Tadiotto F; Da Tos V; D'Ambrosio M; Marangoni A; Ferrari M; Pianta A; Balzano S; Confortin L; Lamonica M; Marin N; Strazzabosco M; Brun E; Mesturino CA; Simoncini M; Zen F; Bax G; Bonsembiante B; Cardone C; Dal Frà MG; Gallo A; Masin M; Piarulli F; Sartore G; Simioni N
    Clin Ther; 2015 Mar; 37(3):574-84. PubMed ID: 25626486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liraglutide Improves Estimated Glomerular Filtration Rate Slopes in Patients with Chronic Kidney Disease and Type 2 Diabetes: A 7-Year Retrospective Analysis.
    Osonoi T; Saito M; Osonoi Y; Douguchi S; Ofuchi K; Katoh M
    Diabetes Technol Ther; 2020 Nov; 22(11):828-834. PubMed ID: 32348695
    [No Abstract]   [Full Text] [Related]  

  • 29. Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials.
    von Scholten BJ; Davies MJ; Persson F; Hansen TW; Madsbad S; Endahl L; Jepsen CH; Rossing P
    J Diabetes Complications; 2017 Jul; 31(7):1164-1168. PubMed ID: 28462892
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial.
    Bouchi R; Nakano Y; Fukuda T; Takeuchi T; Murakami M; Minami I; Izumiyama H; Hashimoto K; Yoshimoto T; Ogawa Y
    Endocr J; 2017 Mar; 64(3):269-281. PubMed ID: 27916783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sitagliptin reduces the urine albumin-to-creatinine ratio in type 2 diabetes through decreasing both blood pressure and estimated glomerular filtration rate.
    Kawasaki I; Hiura Y; Tamai A; Yoshida Y; Yakusiji Y; Ikuno Y; Okada M; Ueno H; Tanaka N; Yamagami K; Fukumoto M; Hosoi M
    J Diabetes; 2015 Jan; 7(1):41-6. PubMed ID: 24661437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors and correlates of systolic blood pressure reduction with liraglutide treatment in patients with type 2 diabetes.
    Wijkman MO; Dena M; Dahlqvist S; Sofizadeh S; Hirsch I; Tuomilehto J; Mårtensson J; Torffvit O; Imberg H; Saeed A; Lind M
    J Clin Hypertens (Greenwich); 2019 Jan; 21(1):105-115. PubMed ID: 30515978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patients with type 2 diabetes having higher glomerular filtration rate showed rapid renal function decline followed by impaired glomerular filtration rate: Japan Diabetes Complications Study.
    Moriya T; Tanaka S; Sone H; Ishibashi S; Matsunaga S; Ohashi Y; Akanuma Y; Haneda M; Katayama S
    J Diabetes Complications; 2017 Feb; 31(2):473-478. PubMed ID: 27396240
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes.
    Mottl AK; Buse JB; Ismail-Beigi F; Sigal RJ; Pedley CF; Papademetriou V; Simmons DL; Katz L; Mychaleckyj JC; Craven TE
    Clin J Am Soc Nephrol; 2018 Nov; 13(11):1693-1702. PubMed ID: 30361335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control.
    Wai B; Kearney LG; Hare DL; Ord M; Burrell LM; Srivastava PM
    Cardiovasc Diabetol; 2012 Feb; 11():14. PubMed ID: 22330091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of liraglutide therapy in 195 Indian patients with type 2 diabetes in real world setting.
    Kesavadev J; Shankar A; Gopalakrishnan G; Jothydev S
    Diabetes Metab Syndr; 2015; 9(1):30-3. PubMed ID: 25605673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of sleep-disordered breathing with diabetes-associated kidney disease.
    Stadler S; Zimmermann T; Franke F; Rheinberger M; Heid IM; Böger CA; Arzt M;
    Ann Med; 2017 Sep; 49(6):487-495. PubMed ID: 28281834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term effectiveness and safety of liraglutide in clinical practice.
    Ponzani P
    Minerva Endocrinol; 2013 Mar; 38(1):103-12. PubMed ID: 23435446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The renoprotective effects of sodium-glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: A systematic review and meta-analysis.
    Wang C; Zhou Y; Kong Z; Wang X; Lv W; Geng Z; Wang Y
    Diabetes Obes Metab; 2019 Apr; 21(4):1018-1026. PubMed ID: 30565382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.